With the FDA’s approval of CAMZYOS® (mavacamten), the first and only cardiac myosin inhibitor for symptomatic New York Heart Association (NYHA) class II-III adult patients, healthcare professionals and patients now have another treatment option that targets HCM at the source. Learn more about the clinical trial data that supported the FDA approval, and how healthcare professionals can prescribe CAMZYOS from Dr. Amy Sehnert, Vice President and Head of Cardiomyopathy and Heart Failure Clinical Development at Bristol Myers Squibb.